Labcorp Holdings Inc.LHNYSE

Overview Intelligence Charts News Fundamentals

Latest News

prnewswire.com

Labcorp Expands Collaboration with PathAI to Deploy FDA-Cleared Digital Pathology Platform Nationwide

AISight® Dx will support fully digital workflows and AI-enabled insights across Labcorp's network of anatomic pathology labs and hospital collaborations to improve efficiency, collaboration and patient care BURLINGTON, N.C., Feb. 23, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with PathAI to deploy AISight® Dx1, an FDA-cleared digital pathology platform, across its national network of anatomic pathology labs and hospital collaborations.

defenseworld.net

Raiffeisen Bank International AG Purchases Shares of 3,068 Labcorp Holdings Inc. $LH

Raiffeisen Bank International AG acquired a new position in Labcorp Holdings Inc. (NYSE: LH) during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,068 shares of the medical research company's stock, valued at approximately $867,000. Other institutional investors

zacks.com

Why Labcorp Holdings (LH) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

defenseworld.net

Aberdeen Group plc Sells 6,077 Shares of Labcorp Holdings Inc. $LH

Aberdeen Group plc reduced its stake in shares of Labcorp Holdings Inc. (NYSE: LH) by 8.1% during the undefined quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 68,544 shares of the medical research company's stock after selling 6,077 shares during the quarter. Aberdeen

defenseworld.net

Labcorp Q4 Earnings Call Highlights

Labcorp (NYSE: LH) executives said the company delivered what CEO Adam Schechter called a "very strong year" in 2025, citing more than 7% revenue growth, 13% adjusted EPS growth, and margin expansion of more than 50 basis points. On the company's fourth-quarter earnings call, management also introduced 2026 guidance that calls for continued growth and further

zacks.com

Here's Why Labcorp Holdings (LH) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

seekingalpha.com

Labcorp Holdings Inc. (LH) Q4 2025 Earnings Call Transcript

zacks.com

Labcorp Q4 Earnings Beat, Revenues Miss, Stock Down in Pre-Market

LH beats Q4 EPS estimates with 18% growth, but a revenue miss and cautious investor reaction push shares lower in pre-market trading.

zacks.com

Labcorp (LH) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

While the top- and bottom-line numbers for Labcorp (LH) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

zacks.com

Labcorp Holdings (LH) Q4 Earnings Surpass Estimates

Labcorp Holdings (LH) came out with quarterly earnings of $4.07 per share, beating the Zacks Consensus Estimate of $3.95 per share. This compares to earnings of $3.45 per share a year ago.

prnewswire.com

Labcorp Announces 2025 Fourth Quarter and Full Year Results

Company Provides 2026 Guidance Financial results from Operations versus 2024: Revenue: Q4 of $3.52 billion vs $3.33 billion; Full year of $13.95 billion vs $13.01 billion Diluted EPS: Q4 of $1.98 vs $1.70; Full year of $10.46 vs $8.84 Adjusted EPS: Q4 of $4.07 vs $3.45; Full year of $16.44 vs $14.57 Free Cash Flow: Q4 of $490.3 million vs. $665.1 million; Full year of $1.21 billion vs $1.10 billion Provided Full-Year 2026 Enterprise Revenue, Adjusted EPS and Free Cash Flow guidance: Revenue of $14.61 billion to $14.79 billion; midpoint growth of 5.4% Adjusted EPS of $17.55 to $18.25; midpoint growth of 8.9% Free Cash Flow of $1.24 billion to $1.36 billion; midpoint growth of 7.8% Expanded partnerships with health systems and regional/local laboratories by signing or closing 13 transactions in 2025 Advanced leadership in specialty testing, launching more than 130 innovative new tests in 2025, including in oncology, women's health, neurology and autoimmune Announced strategic investment to build a modern, state-of-the-art 500,000 square foot Central Laboratory facility to address growth in demand BURLINGTON, N.C.

defenseworld.net

Adam Schechter Sells 5,273 Shares of Labcorp (NYSE:LH) Stock

Labcorp Holdings Inc. (NYSE: LH - Get Free Report) CEO Adam Schechter sold 5,273 shares of the business's stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $284.38, for a total value of $1,499,535.74. Following the completion of the transaction, the chief executive officer directly owned

zacks.com

Will Labcorp (LH) Beat Estimates Again in Its Next Earnings Report?

Labcorp (LH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

zacks.com

Stay Ahead of the Game With Labcorp (LH) Q4 Earnings: Wall Street's Insights on Key Metrics

Besides Wall Street's top-and-bottom-line estimates for Labcorp (LH), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended December 2025.

prnewswire.com

Labcorp Launches First FDA-Cleared Blood Test for Alzheimer's Disease Assessment in Primary Care

Elecsys ® pTau-181 test helps clinicians rule out Alzheimer's disease by identifying patients unlikely to have amyloid pathology Now available nationwide in primary care settings for patients aged 55 and older experiencing symptoms of cognitive decline Expands Labcorp's comprehensive portfolio of Alzheimer's disease blood tests across both primary and specialty care settings BURLINGTON, N.C., Feb. 11, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the nationwide availability of the Elecsys® pTau-181 test, the first and only blood test cleared by the U.S. Food and Drug Administration (FDA) to aid in the initial assessment of Alzheimer's disease in the primary care setting.

defenseworld.net

Labcorp Holdings Inc. $LH Stake Lessened by Jensen Investment Management Inc.

Jensen Investment Management Inc. decreased its holdings in Labcorp Holdings Inc. (NYSE: LH) by 8.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 25,140 shares of the medical research company's stock after selling 2,200 shares during the period. Jensen Investment Management

zacks.com

Labcorp's Q4 Earnings Preview: What's in Store for the Stock?

LH heads into its Q4 earnings report with rising revenue and EPS expectations, driven by Diagnostics momentum, acquisitions and expanding test demand.

prnewswire.com

Labcorp Appoints John H. Sampson, M.D.

BURLINGTON, N.C., Feb. 9, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of John H.

defenseworld.net

Envestnet Asset Management Inc. Sells 15,188 Shares of Labcorp Holdings Inc. $LH

Envestnet Asset Management Inc. decreased its holdings in Labcorp Holdings Inc. (NYSE: LH) by 5.5% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 261,849 shares of the medical research company's stock after selling 15,188 shares during the period. Envestnet Asset Management

defenseworld.net

Labcorp Holdings Inc. $LH Shares Bought by New York State Common Retirement Fund

New York State Common Retirement Fund increased its holdings in Labcorp Holdings Inc. (NYSE: LH) by 12.0% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,795 shares of the medical research company's stock after buying an additional 4,800

Loading news...

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Market Movers

Today's biggest gainers and losers

Market Heatmap

Visual sector performance